Literature DB >> 2560181

Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril.

D I Friedman1, G L Amidon.   

Abstract

The intestinal absorption mechanism of two ACE inhibitor prodrugs, enalapril and fosinopril, was investigated in rats using a single-pass perfusion method. A modified boundary layer solution was applied to determine the apparent intestinal wall permeability. The prodrug enalapril is well absorbed from rat jejunum, whereas the parent drug, enalaprilat, is poorly absorbed. The permeability of enalapril is concentration dependent and is decreased by the dipeptide Tyr-Gly and by cephradine but not by the amino acids L-leucine or L-phenylalanine, indicating a nonpassive absorption mechanism via the small peptide carrier-mediated transport system. In contrast, fosinopril is readily absorbed by a concentration-independent mechanism without the involvement of the peptide carrier.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2560181     DOI: 10.1023/a:1015978420797

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  Passive and carrier-mediated intestinal absorption components of captopril.

Authors:  M Hu; G L Amidon
Journal:  J Pharm Sci       Date:  1988-12       Impact factor: 3.534

2.  Determination of intrinsic membrane transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeabilities.

Authors:  D A Johnson; G L Amidon
Journal:  J Theor Biol       Date:  1988-03-07       Impact factor: 2.691

3.  Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions--parallels and contrasts.

Authors:  A F Lant
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

Review 4.  Clinical pharmacology of the ACE inhibitors.

Authors:  F Fyhrquist
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 5.  Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.

Authors:  P H Vlasses; G E Larijani; D P Conner; R K Ferguson
Journal:  Clin Pharm       Date:  1985 Jan-Feb

6.  Disposition of enalapril in the perfused rat intestine-liver preparation: absorption, metabolism and first-pass effect.

Authors:  K S Pang; W F Cherry; E H Ulm
Journal:  J Pharmacol Exp Ther       Date:  1985-06       Impact factor: 4.030

7.  The physiological disposition and metabolism of enalapril maleate in laboratory animals.

Authors:  D J Tocco; F A deLuna; A E Duncan; T C Vassil; E H Ulm
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

8.  Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ.

Authors:  P J Sinko; G L Amidon
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

9.  Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds.

Authors:  G L Amidon; P J Sinko; D Fleisher
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

10.  Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects.

Authors:  J P Bussien; T F d'Amore; L Perret; M Porchet; J Nussberger; B Waeber; H R Brunner
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

  10 in total
  23 in total

Review 1.  Intestinal peptide transport systems and oral drug availability.

Authors:  C Y Yang; A H Dantzig; C Pidgeon
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

Review 2.  Targeted prodrug design to optimize drug delivery.

Authors:  H K Han; G L Amidon
Journal:  AAPS PharmSci       Date:  2000

3.  Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs.

Authors:  Duxin Sun; Hans Lennernas; Lynda S Welage; Jeffery L Barnett; Christopher P Landowski; David Foster; David Fleisher; Kyung-Dall Lee; Gordon L Amidon
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 4.  Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.

Authors:  Xianhua Cao; Seth T Gibbs; Lanyan Fang; Heather A Miller; Christopher P Landowski; Ho-Chul Shin; Hans Lennernas; Yanqiang Zhong; Gordon L Amidon; Lawrence X Yu; Duxin Sun
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

5.  Permeation of four oral drugs through human intestinal mucosa.

Authors:  Erina Pretorius; Patrick J D Bouic
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

6.  Transport characteristics of L-carnosine and the anticancer derivative 4-toluenesulfonylureido-carnosine in a human epithelial cell line.

Authors:  Carsten Uhd Nielsen; Claudiu T Supuran; Andrea Scozzafava; Sven Frokjaer; Bente Steffansen; Birger Brodin
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

7.  Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements.

Authors:  Caroline A Larregieu; Leslie Z Benet
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

8.  Peptide carrier-mediated transport in intestinal brush border membrane vesicles of rats and rabbits: cephradine uptake and inhibition.

Authors:  H Yuasa; G L Amidon; D Fleisher
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

9.  Suitability of enalapril as a probe of the dipeptide transporter system: in vitro and in vivo studies.

Authors:  R A Morrison; S Chong; A M Marino; M A Wasserman; P Timmins; V A Moore; W J Irwin
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 10.  Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery.

Authors:  J P Bai; G L Amidon
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.